Brain-Controlled Exoskeleton Enables Paralyzed Patient to Walk The device cannot be used outside of the lab yet, but the outcomes are bright. Aquadriplegic patient has walked again acknowledgments to a brain-controlled robotic exoskeleton suit being well-tried in the lab, according to a group of investigators in France. Their assemblage were published (October 3) in The Lancet Neurology. Thibault (whose last name was withheld for privacy), 28 years old at the occurrence of the two-year study, was paralyzed from the shoulders down after a cervical spinal cord injury. Researchers constituted two recording devices on the surface of his brain to accumulate and transmit brain signals. The signals were interpreted into motions with a decoding algorithm, which then sent commands to the exoskeleton. Thibault was able to complete various movement tasks such as walking and reaching for targets, according to a press release.Source: Brain-Controlled Exoskeleton Enables Paralyzed Patient to Walk | The Scientist Magazine®
This year’s Nobel Prize in Physiology or Medicine goes to William Kaelin of the Dana-Farber Cancer Institute and Harvard Medical School, Peter Ratcliffe of the University of Oxford and the Francis Crick Institute, and Gregg Semenza of the Johns Hopkins University School of Medicine “for their discoveries of how cells sense and adapt to oxygen availability,” the Nobel Assembly at the Karolinska Institute announced today (October 7). See “Seeking a Cellular Oxygen Sensor” In 1995, Semenza’s lab was the first to identify the genes that encode hypoxia-inducible factor-1 (HIF-1), a transcription factor that alters cellular responses to low oxygen. His group found that HIF-1 responds to low oxygen levels by controlling which genes are used in a cell. The protein enables cancer cells to live in the low-oxygen conditions found within tumors, and helps the body respond to cardiovascular events that limit oxygen flow to parts of the body.
Stevens specialists build up a procedure dependent on reflectivity designs that can recognize different types of skin cancers, including basal cell carcinoma (left) and squamous cell carcinoma (right). The work could diminish the requirement for pointless biopsies. Credit: Stevens Institute of Technology
The demonstrated innovation will be planned into a handheld gadget that could decrease the requirement for excruciating biopsies by 50 percent — and disturb the $5.3 billion diagnostics showcase.
Indeed, even as well as can’t be expected analyze skin cancer by eye, depending on amplifying glasses to look at suspicious flaws and surgical tools to cut tissue for investigation. Presently, utilizing shortwave beams utilized in cellphones and air terminal security scanners, specialists at Stevens Institute of Technology have built up a strategy that recognizes skin lesions and decides if they are harmful or benevolent — an innovation that could at last be fused into a handheld gadget that could quickly analyze skin cancer without a surgical tool in sight.
The work, driven by Negar Tavassolian, director of the Stevens Bio-Electromagnetics Laboratory, and postdoctoral fellow Amir Mirbeik-Sabzevari, not just can decrease the quantity of superfluous biopsies by 50 percent yet in addition can possibly upset a $5.3 billion symptomatic market for the most widely recognized cancer in the United States, with 9,500 Americans determined to have skin disease every day.
“This could be transformative,” said first creator Mirbeik-Sabzevari, whose work shows up in the September 2019 issue of IEEE Transactions on Medical Imaging. “No other innovation has these abilities.”
Reference: “High-Contrast, Low-Cost, 3-D Visualization of Skin Cancer Using Ultra-High-Resolution Millimeter-Wave Imaging” by Amir Mirbeik-Sabzevari, Erin Oppelaar, Robin Ashinoff and Negar Tavassolian, 4 March 2019, IEEE Transactions on Medical Imaging.